Evidence map›Paper›PMID 39954057›Full record

ArticleActa diabetologica2025

Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.

Giovanni Petralli, Alice Del Zoppo, Chiara Rovera, Francesco Raggi, Antonio Salvati, Diego Moriconi, Mariarosaria Distaso, Maurizia Rossana Brunetto, Anna Solini

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Acta diabetologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Giovanni Petralli *Department of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
Alice Del Zoppo *Department of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
Chiara RoveraDepartment of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
Francesco RaggiDepartment of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
Antonio SalvatiHepatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Diego MoriconiDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Mariarosaria DistasoDepartment of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
Maurizia Rossana BrunettoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Anna SoliniDepartment of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy. anna.solini@unipi.it.ORCID http://orcid.org/0000-0002-7855-8253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimSemaglutide exerts metabolic effects and cardiovascular protection in type 2 diabetes (T2D), also acting on hepatic steatosis and inflammation. No data are, so far, available on the effect of semaglutide on oxidative stress, neither a comparison of injective (InjS) and oral (OrS) formulations has been performed in subjects with T2D and liver steatosis.

methodsIn a real-life, open label, prospective study we compared standard doses of InjS and OrS in targeting liver inflammation and fibrosis and systemic markers of inflammation and oxidative stress by consecutively prescribing InjS or OrS formulation in a 2:1 ratio to sixty T2D + MASLD subjects (T0), observing them for 6 months (T1). Anthropometry, biochemistry and transient elastography (TE) data were collected; hormones, inflammatory cytokines and peroxidation products were measured.

resultsAt baseline, InjS and OrS subjects were similar, except for waist circumference, liver enzymes and Controlled Attenuation Parameter (CAP), a measure of liver steatosis (InjS > OrS, all p < 0.05). Differences emerged in T0-T1 variation between the formulations in HbA1c, lipid profile, blood pressure. CAP significantly decreased only in InjS. GLP-1 quite similarly increased; insulin, glucagon and GIP did not vary. InjS and OrS did not modify TNFα, IL-10 (an anti-inflammatory cytokine) and MCP-1, while IL-18 was reduced only by InjS. When exploring oxidative stress, AGEs were unaffected, Thiobarbituric acid reactive substances decreased in InjS, 4-Hydroxynonenal was reduced in OrS.

conclusionIn T2D + MASLD subjects, InjS, better than OrS, improves metabolic control; a significant reduction of IL-18 by InjS, and a mild anti-oxidative effect of both formulations are reported for the first time.

Indexed as

Diabetes Mellitus, Type 2Fatty LiverGlucagon-Like PeptidesHypoglycemic AgentsOxidative StressAdministration, OralAdultAgedFemaleGlucagon-Like Peptide 1HumansMaleMiddle AgedProspective StudiesSemaglutideGlucagon-Like Peptide 1Glucagon-Like PeptidesHypoglycemic AgentsSemaglutideInjective semaglutideMASLDOral semaglutideOxidative stress

Identifiers

PMID39954057

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.